This Healthcare Giant Had 12 Products That Generated Double-Digit Growth Last Quarter and There's Still Many More in the Pipeline
If you're looking for a top healthcare company to invest in, you may want to consider looking at one that has multiple fast-growing products in its portfolio. By seeking out diversified growth stocks, you can minimize your risk and reduce significant volatility. If a company has a diverse product mix, it has many ways to grow its operations without being too dependent on a single asset.
Amgen (NASDAQ: AMGN) is coming off a strong quarterly performance in which multiple drugs generated double-digit growth. And even better, its growth prospects could get even better in the future.
On Aug. 6, Amgen reported strong second-quarter results for the period ending June 30. Product sales came in at just over $8 billion and rose by 20% year over year. The diversity of the company's portfolio is striking, led by the osteoporosis medication, Prolia, which not only generated $1.2 billion in revenue but grew at a solid clip of 13% year over year.
Source Fool.com
Amgen Inc. Stock
The stock is an absolute favorite of our community with 28 Buy predictions and no Sell predictions.
With a target price of 304 € there is a slightly positive potential of 4.74% for Amgen Inc. compared to the current price of 290.25 €.
